Nexalin Technology (NXL) Cash & Equivalents (2021 - 2026)

Nexalin Technology has reported Cash & Equivalents for 6 years, with the latest figure at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 94.19% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 million (up 94.19% YoY), and the FY2025 full-year result was $3.1 million, up 434.12% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $1.2 million, down from $3.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $7.9 million in Q3 2022, with the low at $81421.0 in Q3 2024.
• Average Cash & Equivalents over 5 years is $2.6 million, with a median of $1.6 million recorded in 2024.
• Year-over-year, Cash & Equivalents sank 95.4% in 2023 and surged 4521.17% in 2025.
• Tracing NXL's Cash & Equivalents over 5 years: stood at $6.8 million in 2022, then slumped by 65.33% to $2.4 million in 2023, then sank by 75.74% to $574485.0 in 2024, then soared by 434.12% to $3.1 million in 2025, then sank by 60.63% to $1.2 million in 2026.
• The last three Cash & Equivalents figures came in at $1.2 million (Q1 2026), $3.1 million (Q4 2025), and $3.8 million (Q3 2025), per Business Quant data.

Peer Comparison